Aged Aged 80 and over Chemoradiotherapy/*mortality/*statistics & numerical data Combined Modality Therapy Cystectomy/*mortality/*statistics & numerical data Disease-Free Survival Female Humans Male Middle Aged Neoplasm Invasiveness Postoperative Complications/mortality/prevention & control Prevalence Radiation Injuries/mortality/prevention & control Risk Factors Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*mortality/*therapy

Adult Aged Aged 80 and over Humans Magnetic Resonance Imaging/standards Middle Aged Muscle Neoplasms/*diagnosis Neoplasm Invasiveness Sensitivity and Specificity Urinary Bladder Neoplasms/*diagnosis Bladder cancer Local staging Magnetic resonance imaging Meta-analysis Muscle-invasive bladder cancer Systematic review

Aged Catheterization Chemotherapy Adjuvant Feasibility Studies Female Humans *Laser Therapy Length of Stay Male Middle Aged Operative Time Postoperative Complications/etiology Time Factors Treatment Outcome Urinary Bladder Neoplasms/drug therapy/pathology/*radiotherapy/*surgery Bladder tumor Laser enucleation of bladder tumor Meta-analysis Transurethral resection of bladder tumor (TURBT)

Age Factors Aged Aged 80 and over Clinical Decision-Making *Cystectomy/adverse effects/mortality Disease-Free Survival Female Geriatric Assessment Humans Life Expectancy Male Middle Aged Neoplasm Invasiveness Odds Ratio Patient Selection Quality of Life Radiotherapy/adverse effects/mortality Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/mortality/pathology/*therapy Complications Elderly Mibc Outcome

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence

Aged Aged 80 and over *Biomarkers Tumor Cluster Analysis Cohort Studies Female Gene Expression Profiling Humans Immunohistochemistry Male Middle Aged Mutation Neoplasm Invasiveness Neoplasm Staging Neoplasms Basal Cell/*diagnosis/genetics/*metabolism/mortality Prognosis Survival Analysis Tissue Array Analysis Urinary Bladder Neoplasms/*diagnosis/genetics/*metabolism/mortality Biomarker Bladder cancer

Aged Blood Loss Surgical Cystectomy/*adverse effects/*methods Female Humans Length of Stay Male Middle Aged Operative Time Postoperative Complications/etiology Quality of Life Randomized Controlled Trials as Topic Robotic Surgical Procedures/*adverse effects/*methods Treatment Outcome Urinary Bladder/*surgery Urinary Bladder Neoplasms/surgery Urinary Diversion/*adverse effects/*methods

Adult Aged Aged 80 and over Female Humans Middle Aged *Parity Risk Assessment Urinary Bladder Neoplasms/*epidemiology/etiology/physiopathology Bladder cancer Meta-analysis Parity Women’s health

Adult *Amino Acid Substitution Case-Control Studies DNA-Binding Proteins/*genetics Female Gene Expression *Genetic Predisposition to Disease Humans Male Middle Aged Odds Ratio *Polymorphism Single Nucleotide Risk Factors Smoking/physiopathology Tobacco Use/physiopathology Urinary Bladder Neoplasms/diagnosis/*genetics/pathology

Adult Aged Aged 80 and over Antibodies Monoclonal/therapeutic use Antibodies Monoclonal Humanized/therapeutic use B7-H1 Antigen/*antagonists & inhibitors/genetics CTLA-4 Antigen/*antagonists & inhibitors/genetics Clinical Trials as Topic Female Genes cdc/drug effects Humans Ipilimumab Male Middle Aged Neoplasm Metastasis/*drug therapy/genetics/pathology Nivolumab Urinary Bladder Neoplasms/*drug therapy/genetics/pathology Bladder cancer immunotherapy Checkpoint inhibitor Pembrolizumab

Adult Aged Aged 80 and over Female *Fluorodeoxyglucose F18 Humans Lymphatic Metastasis Male Middle Aged Neoplasm Staging *Positron Emission Tomography Computed Tomography *Radiopharmaceuticals Reproducibility of Results Retrospective Studies Urinary Bladder Neoplasms/*drug therapy/*pathology Bladder cancer Lymph nodes Positron emission tomography Preoperative staging Urinary bladder neoplasms

Adult Aged Aged 80 and over Biomarkers Tumor/*metabolism Cyclin-Dependent Kinase Inhibitor p16/*metabolism *Down-Regulation Female Gene Expression Regulation Neoplastic Humans Lymphatic Metastasis Male Middle Aged Prognosis Survival Analysis Urinary Bladder Neoplasms/metabolism/mortality/*pathology